TIBURIO THERAPEUTICS

tiburio-therapeutics-logo

Tiburio Therapeutics is a developer of drug compounds intended to treat tumors and endocrine diseases.The company's compounds aid in the treatment of non-functioning pituitary adenoma using a dopamine-somatostatin chimeric molecule that has the potential to shrink or halt tumor growth, providing patients with effective treatment for rare neuroendocrine tumors and endocrine diseases.

#SimilarOrganizations #People #Financial #Website #More

TIBURIO THERAPEUTICS

Social Links:

Industry:
Biotechnology Health Care Medical Pharmaceutical

Founded:
2018-01-01

Address:
Cambridge, Massachusetts, United States

Country:
United States

Website Url:
http://www.tiburio.com

Total Employee:
1+

Status:
Active

Contact:
+1 (617) 231-6050

Email Addresses:
[email protected]

Total Funding:
31 M USD

Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Apple Mobile Web Clips Icon Google Tag Manager Google Analytics LetsEncrypt Amazon SSL By Default Organization Schema Google Universal Analytics


Similar Organizations

amylyx-pharmaceuticals-logo

Amylyx Pharmaceuticals

Amylyx Pharmaceuticals specializes in providing solutions for Alzheimerโ€™s and other diseases of the brain.

dyne-therapeutics-logo

Dyne Therapeutics

Dyne Therapeutics is a developer of targeted therapies intended for serious muscle diseases.

engrail-therapeutics-logo

Engrail Therapeutics

Engrail Therapeutics is a developer of medicines to transform the lives of patients with life-limiting diseases of the nervous system.

entrada-therapeutics-logo

Entrada Therapeutics

Entrada Therapeutics is a developer of novel therapeutics intended to treat devastating diseases.

esperion-logo

Esperion

Esperion discovers and develops pharmaceutical products for the treatment of cardiovascular and metabolic diseases.

neurogene-logo

Neurogene

Neurogene is a developer of genetic medicines intended to improve patient outcomes for neurological disorders.

nimblerx-logo

NimbleRx

Nimble provides a pharmacy experience centered around the patient's needs to provide a more streamlined workflow.

obsidian-therapeutics-logo

Obsidian Therapeutics

Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy.

rome-therapeutics-logo

ROME Therapeutics

ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome.

vico-therapeutics-logo

Vico Therapeutics

Vico Therapeutics is a developer of ribonucleic acid (RNA) modulating therapies.

Current Employees Featured

michael-culler_image

Michael Culler
Michael Culler Scientific Founder and Chairman, Scientific Advisory Board @ Tiburio Therapeutics
Scientific Founder and Chairman, Scientific Advisory Board

Founder


chris-adams_image

Chris Adams

imran-babar_image

Imran Babar

james-mcarthur_image

James McArthur

michael-culler_image

Michael Culler

Investors List

lundbeckfond-ventures_image

Lundbeckfonden Ventures

Lundbeckfonden Ventures investment in Series A - Tiburio Therapeutics

new-enterprise-associates_image

New Enterprise Associates

New Enterprise Associates investment in Series A - Tiburio Therapeutics

alexandria-venture-investments_image

Alexandria Venture Investments

Alexandria Venture Investments investment in Series A - Tiburio Therapeutics

longitude-capital_image

Longitude Capital

Longitude Capital investment in Series A - Tiburio Therapeutics

Official Site Inspections

http://www.tiburio.com

  • Host name: a904c694c05102f30.awsglobalaccelerator.com
  • IP address: 76.223.54.146
  • Location: Seattle United States
  • Latitude: 47.54
  • Longitude: -122.3032
  • Metro Code: 819
  • Timezone: America/Los_Angeles
  • Postal: 98108

Loading ...

More informations about "Tiburio Therapeutics"

Tiburio Therapeutics - Crunchbase Company Profile & Funding

Tiburio Therapeutics is a developer of drug compounds intended to treat tumors and endocrine diseases.The company's compounds aid in the treatment of non-functioning pituitary adenoma โ€ฆSee details»

Tiburio Therapeutics Inc. Company Profile - Dun & Bradstreet

Find company research, competitor information, contact details & financial data for Tiburio Therapeutics Inc. of Cambridge, MA. Get the latest business insights from Dun & Bradstreet.See details»

Tiburio Therapeutics Company Profile 2024: Valuation, Funding ...

Tiburio Therapeutics General Information Description. Provider of novel treatments designed to treat rare neuroendocrine tumors and rare endocrine diseases. The company's clinical stage โ€ฆSee details»

Tiburio Therapeutics - Contacts, Employees, Board Members, โ€ฆ

Tiburio Therapeutics has 1 current employee profile, Scientific Founder and Chairman, Scientific Advisory Board Michael Culler. Michael Culler Scientific Founder and Chairman, Scientific โ€ฆSee details»

Tiburio Therapeutics - VentureRadar

Tiburio is a clinical stage biopharmaceutical company dedicated to advancing novel treatments for rare neuroendocrine tumors and rare endocrine diseases where there is significant patient โ€ฆSee details»

Tiburio Therapeutics Inc - Company Profile and News

Company profile page for Tiburio Therapeutics Inc including stock price, company news, executives, board members, and contact informationSee details»

Tiburio Therapeutics - Craft

Tiburio Therapeutics is a biopharmaceutical company, which is dedicated to advancing novel treatments for rare neuroendocrine tumors and rare endocrine diseases. The Company's โ€ฆSee details»

Tiburio Therapeutics - Funding, Financials, Valuation & Investors

Tiburio Therapeutics is a developer of drug compounds intended to treat tumors and endocrine diseases. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. ... How much โ€ฆSee details»

Tiburio Therapeutics CEO and Key Executive Team | Craft.co

Tiburio Therapeutics's Director is Chris Adams. Other executives include Sandip K. Agarwala, Director; Michael D. Culler, Scientific Founder and Chairman, Scientific Advisory Board and 4 โ€ฆSee details»

Cydan Announces Formation of Tiburio Therapeutics Inc. to โ€ฆ

Jan 4, 2019 Tiburio is a clinical stage biopharmaceutical company dedicated to advancing novel treatments for rare neuroendocrine tumors and rare endocrine diseases where there is โ€ฆSee details»

Tiburio launches with $31M and clinical-stage drugs for rare โ€ฆ

Jan 3, 2019 Tiburio will start phase 2-enabling studies for TBR-760 immediately and planning to start a phase 2 trial in NFPA patients in the second half of 2019. The series A, drawn from โ€ฆSee details»

Tiburio Therapeutics | Lundbeckfonden

Tiburio Therapeutics is a drug development company that develops novel small molecule treatments for potentially life-threatening rare neuroendocrine tumours and endocrine diseases โ€ฆSee details»

Tiburio Therapeutics - The Lundbeck Foundation

Tiburio Therapeutics is a drug development company that develops novel small molecule treatments for potentially life-threatening rare neuroendocrine tumours and endocrine diseases โ€ฆSee details»

Tiburio Therapeutics | CipherBio

Explore Tiburio Therapeutics's investment information, scientific platforms, therapeutic approaches, indications and more here!See details»

Tiburio Therapeutics: A Map for Selling to this Stealth Biotech โ€ฆ

Oct 21, 2020 Heather Halem, Ph.D. - Vice President, Research of Tiburio Therapeutics, Heather brings more than 17 years of pharmaceutical experience to Tiburio with strong expertise in โ€ฆSee details»

Cydan Announces Formation of Tiburio Therapeutics Inc. to โ€ฆ

Jan 3, 2019 Tiburio is a clinical stage biopharmaceutical company dedicated to advancing novel treatments for rare neuroendocrine tumors and rare endocrine diseases where there is โ€ฆSee details»

Tiburio Therapeutics | Biotechnology - The Pharmaletter

Tiburio is a privately-held biopharma focused on developing treatments for rare neuroendocrine tumors and rare endocrine diseases. It is the third company to be launched by the USA-based โ€ฆSee details»

Developing Transformative Treatments for Rare Endocrine Diseases

Jul 1, 2020 Tiburio is actively taking TBR-760 to the IND phase and expects to initiate a phase II clinical trial in patients with NFPA in the second half of 2020. Targeting Rare Endocrine โ€ฆSee details»

Tiburio: Investing in Traditional Drug Development in the Era of โ€ฆ

Jan 3, 2019 Third, an excellent CEO has joined Tiburio โ€“ Abraham Ceesay, who has 17 years of experience leading biopharmaceutical companies and was most recently Chief Operating โ€ฆSee details»

Tiburio Announces Publication of Preclinical TBR-760 Data

May 11, 2020 Tiburio is dedicated to developing transformative treatments for rare endocrine diseases. The company is advancing a unique class of chimeric compounds that has the โ€ฆSee details»

linkstock.net © 2022. All rights reserved